Clinical Trial Detail

NCT ID NCT02345772
Title Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Western Regional Medical Center
Indications

Her2-receptor positive breast cancer

Therapies

Fulvestrant

Docetaxel + Pertuzumab + Trastuzumab

Age Groups: adult

Additional content available in CKB BOOST